FDA Approves TAPENTADOL — Hikma Pharmaceuticals USA Inc.

Hikma Pharmaceuticals USA Inc. has secured approval for oral tapentadol, a generic version of NDA022304 set to expand its robust opioid portfolio alongside Nucynta. With the move to offer a lower-cost alternative to the branded manufacturer, Hikma is strategically positioning itself to capture a larger slice of the growing chronic pain market amid increasing generic substitution.